Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer

Abstract

Purpose: In 2014, the US Food and Drug Administration approved the first targeted agent, bevacizumab, in the treatment of advanced stage, persistent, or recurrent cervical cancer. This oncologic milestone has catalyzed interest in the investigation of alternate therapies, including immunotherapy, in an effort to extend life and possibly cure patients with advanced stage disease.Methods: This review article focuses on the evolving paradigm of immunotherapy in the treatment of cervical cancer, describing the biologic basis of this treatment modality and discussing applicable Phase I to II clinical trials.Findings: To date several trials have been conducted exploring vaccine-based therapies, adoptive T-cell therapy, and immune-modulating agents in patients with cervical cancer with promising results.Implications: Immunotherapy represents a promising therapeutic paradigm in the treatment of advanced cervical cancer. Additional investigation is warranted to try and identify alternate immune targets and predictors of response, allowing for the selection of patients most likely to benefit from immune-based treatments. (Clin Ther. 2015;37:20-38) & 2015 Elsevier HS Journals, Inc. All rights reserved.

Microwave-assisted synthesis of polypyridyl ruthenium(ii) complexes as potential tumor-targeting inhibitors against the migration and invasion of Hela cells through G2/M phase arrest

“…The treatment of cervical cancer faces one of the most challenging problems in clinical oncology in that there are few effective treatments to block the metastasis of cervical cancer cells. [12][13][14][15] Ruthenium complexes have always been regarded as some of the most potential antitumour inhibitors owing to their decent antitumour activity [16][17][18][19][20] and low toxicity. [21][22][23][24] A number of Ru complexes have been designed and their anti-metastasis activities against various tumours have been investigated extensively.…”

Analysis of Anticancer Activity and Chemical Sensitization Effects of Dendropanax morbifera and Commersonia bartramia Extracts

“…phase I trials are being assessed for the application of immunotherapy in endometrial cancer (14), while several immunotherapies targeting human papilloma virus are under investigation for cervical cancer (15).…”

The Epigenetic Landscape in the Treatment of Gynecologic Malignancies

“…[73][74][75][76] This milestone represented the fi rst me a targeted agent resulted in an overall survival advantage in the gynecologic cancer arena, resul ng in FDA approval of bevacizumab in the treatment of advanced-stage or recurrent cervical cancer. 77 Cervical cancer is unique among gynecologic cancers because several risk factors are well established, and the causa ve agent, human papillomavirus (HPV), is known. This was confi rmed in the molecular characteriza on of cervical cancer, where 95% specimens were found to be HPV posi ve.…”